CytoMed Therapeutics Limited (GDTC) NASDAQ

2.01

+0(+0.00%)

Updated at October 03 04:00PM

Currency In USD

CytoMed Therapeutics Limited

Address

1 Commonwealth Lane, No. 08-22

Singapore, 149544

Singapore

Phone

65 6250 7738

Sector

Healthcare

Industry

Biotechnology

Employees

43

First IPO Date

April 14, 2023

Key Executives

NameTitlePayYear Born
Mr. Chee Kong ChooExecutive Chairman38,1431958
Dr. Jieming Zeng M.D., Ph.D.Chief Scientific & Medical Officer and Director102,0371974
Ms. Yvonne GohChief Financial Officer01990
Ms. Yoong Ying TanChief Corporate Officer01989
Dr. Tien Wee Luk M.D.Chief Clinical Officer01986

Description

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.